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Background: Dry socket is one of the most common complications that develops after the extraction of a perma-
nent tooth, and its prevention is more effective than its treatment.
Objectives: Analyze the efficacy of different methods used in preventing dry socket in order to decrease its inci-
dence after tooth extraction. 
Material and Methods: A Cochrane and PubMed-MEDLINE database search was conducted with the search 
terms “dry socket”, “prevention”, “risk factors”, “alveolar osteitis” and “fibrynolitic alveolitis”, both individually 
and using the Boolean operator “AND”. The inclusion criteria were: clinical studies including at least 30 patients, 
articles published from 2005 to 2015 and written in English. The exclusion criteria were case reports and nonhu-
man studies.
Results: 30 publications were selected from a total of 250. Six of the 30 were excluded after reading the full text. 
The final review included 24 articles: 9 prospective studies, 2 retrospective studies and 13 clinical trials. They 
were stratified according to their level of scientific evidence using SIGN criteria (Scottish Intercollegiate Guide-
lines Network).
Conclusions: All treatments included in the review were aimed at decreasing the incidence of dry socket. Locally 
administering chlorhexidine or applying platelet-rich plasma reduces the likelihood of developing this complica-
tion. Antibiotic prescription does not avoid postoperative complications after lower third molar surgery. With 
regard to risk factors, all of the articles selected suggest that patient age, history of previous infection and the diffi-
culty of the extraction are the most common predisposing factors for developing dry socket. There is no consensus 
that smoking, gender or menstrual cycles are risk factors.
Taking the scientific quality of the articles evaluated into account, a level B recommendation has been given for 
the proposed-procedures in the prevention of dry socket.
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Introduction
Dry socket is the most common complication following 
tooth extraction (1) and one of the most studied com-
plications in dentistry (2). There are up to 17 different 
definitions for the clinical diagnosis of dry socket (3). 
Blum (4) described dry socket as the presence of “post-
operative pain in and around the extraction site, which 
increases in severity at any time between one and three 
days after the extraction, accompanied by a partially or 
totally disintegrated blood clot within the alveolar sock-
et, with or without halitosis” (4) excluding any other 
cause of pain on the same side of the face.
Its incidence is approximately 3% for all routine extrac-
tions and can exceed 30% for impacted mandibular third 
molars (5), and many factors have been cited as contrib-
uting to the occurrence of dry socket including difficult 
or traumatic extractions, female gender, tobacco use, 
oral contraceptive use and pre-existing infections (6).
It has been suggested that increased local fibrinolytic 
activity is the main etiological factor in developing dry 
socket. Increased in fibrinolytic activity could result in 
the premature loss of the intraalveolar blood clot after 
extraction (7). The fibrinolysis is the result of plasmino-
gen pathway activation, which can be achieved via di-
rect (physiologic) or indirect (nonphysiologic) activator 
substances. Direct activators are released after trauma 
to the alveolar bone cells. Indirect activators are secret-
ed by bacteria (8). Apart from its role in the fibrinolytic 
process, the exact etiology of dry socket is not well un-
derstood (9, 10).
The treatment of alveolitis depends on each profession-
al’s clinical experience (11) primarily due to its complex 
etiology, although substantial research has been pub-
lished on the management of dry socket.
The Cochrane Collaboration published a review on lo-
cal procedures for managing dry socket, and concluded 
there was no evidence to support any of the procedures 
should be included in its treatment (12).
The aim of this systematic review is to analyze the dif-
ferent methods used for preventing dry socket. The fol-
lowing question emerged: what is the most effective 
method for preventing dry socket and reducing its in-
cidence? In addition, would identifying the risk factors 
for dry socket reduce its incidence?
Material and Methods
A Cochrane and PubMed-MEDLINE databases search of 
articles was conducted between May 2015 and December 
2015. The key words “dry socket”, “risk factors”, “alveo-
lar osteitis” and “fibrynolitic alveolitis” were used.  After 
that, the terms were combined using the Boolean opera-
tor “AND”, in order to obtain the articles that included 
two or more of the words used in the search.
The inclusion criteria were clinical studies that includ-
ed at least 30 patients published from 2005 to 2015 and 
written in English. The exclusion criteria were case re-
ports and nonhuman studies.
Articles were selected by one of the authors first reading 
the titles and abstracts and then reading the full text of 
the articles that met the inclusion criteria (Fig. 1). The 
PRISMA guideline for systematic reviews was followed 
during the process of selection of the articles, and these 
were assessed using the Cochrane Collaboration’s tool 
for assessing risk of bias.
Results
The complete texts of 30 articles were analyzed out of 
the 250 studies initially obtained from the search. Six 
of these 30 articles were excluded because they had no 
direct relationship with the subject and 24 relevant ar-
ticles were finally selected to be included in our sys-
tematic review: 9 prospective studies, 2 retrospective 
studies and 13 clinical trials (Fig. 1).
The articles were stratified according to their level of 
evidence, using SIGN criteria (Scottish Intercollegiate 
Guidelines Network) (13) (Tables 1,2), with a result of 9 
articles with a 2+ scientific evidence level and 15 with a 
2- scientific evidence level. According to the Cochrane 
assessment tool, the 9 articles had a low risk of bias and 
the other 15 articles had an unclear risk of bias.
The articles we reviewed analyzed three different meth-
ods for preventing dry socket: chlorhexidine (14-23), an-
tibiotic therapy (24-31) and platelet-rich plasma (32,33). 
There were also some articles which analyzed other 
methods that were also included in the review (34-37). 
All these results can be seen on Table 3, 3 continue.
The concentration and formulation of chlorhexidine in 
Fig. 1. Flow of articles through the systematic 
review
Initial search (n=250)
Screening of duplicated register (n=234)
Screening of titles and abstracts (n=211)
Screening of full text articles (n=30)
6 excluded articles:
4 literature reviews
2 not about dry socket
Articles included in analysis (n=24)





At least one meta-analysis, randomized study or clinical study classified as 
1+++ and directly applicable to the target population in the guide; or a volu-
me of scientific evidence including studies rated as 1+ and with great consis-
tency among them
B
A body of evidence including studies rated as 2++, directly applicable to the 
target population of the guide and demonstrating great consistency bet-
ween them; or extrapolated evidence from studies rated as 1++ or 1+
C
A body of evidence including studies rated at 2+ directly applicable to the 
target population of the guide and demonstrating great consistency among 
them; or extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+
Table 1.  SIGN Criteria (Scottish Intercollegiate Guidelines Network) (13).
Level of evidence Diagnosis
1 ++ High quality meta-analysis, high quality randomized studies or clinical studies with very low risk of bias
1 + Well performed meta-analysis, well performed randomized studies or clinical studies with little risk of bias
1- Meta-analysis, randomized study or clinical study with high risk of bias
2++ High quality randomized studies, case control or cohort studies. Cohort studies or case-control studies with very low risk of bias and with a high probability of establishing a causal relationship
2+ Well-performed cohort or case-control  studies with low risk of bias and a moderate probability of establishing a causal relationship
2- Cohort or case-control studies at high risk of bias and significant risk that the relationship is not causal
3 Non-analytical studies, such as case reports and case series
4 Expert opinion
Studies classified as 1- and 2- should not be used in the process of developing recommendations for its high poten-
tial for bias
Table 2. Levels of scientific evidence SIGN (13).




















Freudenthal et al. 2015 (16) 
 
2+ 95 
GROUP 1 (control) n = 47 
Placebo gel 
19 
GROUP 2 n = 48 
CHX gel 0.2% 
23 
Rubio-Palau  et al . 2015 (17) 
 
2+ 160 
GROUP 1 (control) n = 80 
Placebo gel 
17.5 
GROUP 2 n = 80 
CHX gel 0.2% 
22.5 
Jesudasan  et al. 2015 (23) 
 
2+ 270 
GROUP 1 (control) n = 90 
Placebo gel 
10 
GROUP 2 n =90 
CHX gel 0.2% 
2.2 
GROUP 3 n = 90 
Eugenol paste 
0 
Rodríguez-Pérez   et al . 2013 (15) 
 
2- 88 
GROUP 1  n = 46 
CHX gel 0.2% 
13 
GROUP 2 n = 42 
CHX gel 1% 
7 
Hita-Iglesias  et al . 2008 (14) 2- 73 
GROUP 1 n = 41 
CHX gel 0.2% 
7.5 
GROUP 2 n =32 
CHX  mouthwash 0.12% 
25 
Sridhar  et al. 2011 (22) 2- 100 
GROUP 1 (control) n =50 8 
GROUP 2 n = 50 
 CHX  mouthwash 0.2% 
0 
Torres-Lagares  et al.  2006 (18) 2- 30 
GROUP 1 (control) n = 13 30.7 
GROUP 2 n = 17 
CHX Gel  0.2% 
17.6 
Torres-Lagares  et al. 2006 (20) 2+ 103 
GROUP 1 (control) n = 50 
Placebo gel 
11 
GROUP 2 n = 53 
CHX gel 0.2% 
30 
Torres-Lagares  et al. 2010 (19) 2+ 38 
GROUP 1 (control) n = 24 17 
GROUP 2 n =14 
CHX gel 0.2% 
7 
Haraji and Rakhshan 2015 (21) 2+ 90 
GROUP 1 (control) n = 45 17.8 
GROUP 2 n = 45 
CHX gel 0.2% 
6.7 
ANTIBIOTICS 
Bortoluzzi  et al . 2013 (24) 2+ 50 
GROUP 1 (control) n = 12 8.3 
GROUP 2 n = 12 
Amoxicillin 2 mg 
Dexamethasone 8 mg 
0 
GROUP 3 n = 14 
Amoxicillin 2 mg 
Placebo 8 mg 
8.3 
GROUP 4 n = 12 
Placebo 2 mg 
Dexamethasone 8 mg 
0 
Table 3. Different methods in the prevention of dry socket.




Lee  et al. 2014 (25) 2- 1222 
GROUP 1 (control) n = 783 1 
GROUP 2 n = 439 
Cefditoren pivoxil 100 mg 
0.7 
Halpern and Dodson 2007 (31) 2+ 118 
GROUP 1 (control) n = 59 
Placebo 
0 
GROUP 2 n = 59 
Penicillin (15,000 units per 
kilogram) 
0 
Xue  et al. 2015 (26) 2+ 414 
GROUP 1 (control) n = 207 3 
GROUP 2 n = 207 
Amoxicillin 500 mg 
2 
Bezerra  et al. 2011 (27) 2+ 136 
GROUP 1 (control) n = 68 
Placebo 
1.5 
GROUP 2 n = 68 
Amoxicillin 500 mg 
1.5 
Kaczmaryck  et al. 2007 (28) 2+ 86 
GROUP 1 (control) n = 27 
Placebo 
14.8 
GROUP 2 n = 31 
Clindamycin 600 mg + 
Placebo for 5 days 
7.1 
GROUP 3 n = 28 
Clindamycin 600 mg +  300 
mg for 5 days 
14.8 
Sanchis  et al. 2004 (29) 2+ 200 
GROUP 1 (control) n = 100 1 
GROUP 2 n = 100 
Tetracycline 9 mg 
3 
Reekie  et al. 2005 (30) 
2+ 302 




GROUP 2 n = 152 
Metronidazole gel 25% 
5.3 
PLATELET-RICH PLASMA 
Eshghpour  et al. 2013 (39) 2+ 156 
GROUP 1 (control) n = 78 12.5 
GROUP 2  n = 78 
Platelet-rich plasma 
5.5 
Rutkowski  et al. 2007 (33) 2+ 904 
GROUP 1 (control)  n = 491 9.6 




Osunde  et al. 2014 (34) 2- 120 
GROUP 1 (control)  n = 80 25 
GROUP 2  n = 40 
Warm saline mouth rinse 
2.5 
Cho  et al. 2015 (35) 2- 3869 
Absorbable type I collagen 
sponge 
1.14 
Tek  et al. 2014 (36) 2- 100 
GROUP 1 (control)  n = 50 14 
GROUP 2  n = 50 
Topical hemostatic agent  
16 
Tolstunov 2012 (37) 2- 70 
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Table 3 continue. Different methods in the prevention of dry socket.
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preventing dry socket used 0.12%, 0.2% and 1% gel for-
mulation (15-21,23) or 0.2% chlorhexidine mouthwash 
(22) in the articles reviewed. In only one article (14) was 
a comparison made between the two formulations. The 
results obtained are rather contradictory, because the gel 
group showed a major decrease in dry socket incidence 
in the last article (14), but the mouthwash formulation 
showed better results in all the other articles (21).
The antibiotic used, the dosage and the route of ad-
ministration were also different in each article which 
analyzed the efficacy of this method for preventing dry 
socket, this being prescribing amoxicillin (or clindamy-
cin in the case of allergy to penicillin) one of the most 
studied medications, in 500 mg or 2 g doses. Bortoluzzi 
et al. (24) studied the synergic effect of amoxicillin with 
dexamethasone. The other antibiotics studied were ced-
itoren pivoxil (a third-generation oral cephalosporin) 
(25), tetracycline (29) and topical metronidazole (30). 
It must be noted that the articles described third molar 
extractions except Reekie et al. (30), who also included 
premolar extractions in their sample.
With regard to the risk factor identification, 9 articles 
specifically dealt with the major risk factors for dry 
socket; all of the articles were prospective studies. Five 
articles (38-42) analyzed risk factors after third molar 
extractions, while four articles (43-46) did so after ei-
ther surgical or non surgical extractions. Therefore, this 
is a representative sample for dry socket after all types 
of extractions.
Risk factors such as previous surgical infection (37), the 
reason for extraction (44-45), tobacco use (38,43-44), 
anesthesia, the amount of anesthesia (38), menstrual 
cycles (38), older patient age (41), surgical difficulty 
(41,43,44) and some drugs (45) were associated with an 
increased risk of alveolar osteitis. However, the patient’s 
gender wasn’t considered to be a risk (40).
Discussion
- Dry socket prevention
After analyzing chlorhexidine’s efficacy as a way of 
preventing dry socket, the ten articles included in this 
review didn’t come to any conclusive results. Five of 
these articles suggested that applying chlorhexidine 
after the extraction to the alveoli did not yield better 
results than the control group, although one article did 
find significant differences (21). Mouthwash (22) used 
pre and post extraction did show a significant decrease 
in dry socket incidence. Nevertheless, a comparative 
study between the two formulations (15) obtained bet-
ter results for the gel group. This results agree with 
Mínguez-Serra’s et al. review (47), and as the authors 
themselves point out, mouthwash is a more economical 
alternative and therefore perhaps more recommendable 
in public health systems.
In addition, when comparing chlorhexidine (in gel for-
mulation) with another preventive method like eugenol 
(Alvogyl®) (23), the latter showed better results not only 
decreasing pain and inflammation, but also by promot-
ing alveolar mucosa healing.
With respect to antibiotic prescription, there is a con-
sensus between the eight articles included in the review. 
Seven of them conclude that the prophylactic regimen is 
unnecessary, since it does not prevent dry socket. Even 
so, Halpern and Dodson (31) do describe the beneficial 
effects of intravenous penicillin prescription thereby re-
ducing postoperative inflammatory complications, but 
not on dry socket in particular. In their meta-analysis, 
Ren et al. (48) conclude that there is a reduction in dry 
socket incidence when an antibiotic prescription is per-
formed preoperatively, but they express their doubts 
about the risk/benefit ratio; in order to avoid 1 case of 
dry socket, 13 patients have to take antibiotics, thereby 
increasing resistance and the other drawbacks it entails. 
It is still a very controversial issue.
Platelet-rich plasma may also have a preventive effect as 
well as being efficient in dry socket management (11). 
The two articles included in the review (32-33) show 
significant differences in dry socket incidence with re-
spect to the control group. However, as Barona-Dorado 
et al. (49) points out in their systematic review, more 
randomized clinical trials are needed before suggesting 
this method.
In relation to the other methods described for dry socket 
prevention, the results were diverse. Both warm saline 
mouth rinse (34) and absorbable collagen sponges (35) 
showed significant results, as well as immediate post-
extraction socket irrigation. The topical hemostatic 
agent, Ankafer Blood Stopper (ABS; Ankaferd Health 
Products Ltd., Istanbul, Turkey) (36), a traditional me-
dicinal plant extract product used as a hemostatic agent, 
didn’t achieve better results than the control group.
- Risk factors
Regarding dry socket risk factors, Chuang et al. (40) 
makes a distinction between modifiable and non-modi-
fiable risk factors. Despite the importance of their iden-
tification, most of them cannot be modified by the clini-
cian.
These authors point out that the only modifiable factor 
is the pre- surgical infection site that could be inocu-
lated with microorganisms from the external environ-
ment in the newly exposed socket after extraction (43). 
Partharsarathi et al. (46) goes on to explain in their ar-
ticle that periodontal extractions have an odds ratio of 
7.5 for developing dry socket. This fact could be related 
to all pathogens involved in dry socket etiology.
Another modifiable factor may be tobacco use, even 
though there is no clear data indicating a higher predis-
position in smoking patients. Three articles (38, 43, 45) 
describe a greater incidence in smokers, especially in 
the 24 hours following the extraction, but neither Haraji 
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or Rakhshan (42) and Parhasarathi et al. (46) found sig-
nificant results, the latter pointing out an inadequate 
statistical analysis as the cause of this misconception. 
In fact, the pathway that links tobacco to dry socket is 
still unknown, the predominant theory suggesting that 
mechanical clot dislodgement occurs with the sucking 
motion in smoking (46), although the formation of gran-
ulation tissue or a decreased local immune and inflam-
matory response (43) may also play a role.
Only Eshghpour and Nejat (38) describe the amount of 
anesthesia used during the extraction as a possible risk 
factor. They explain that epinephrine might attenuate 
healing by reducing bleeding and oxygen tension and 
also increases fibrinolysis. They also observed that the 
number of cartridges used in local anesthesia was deter-
mining factor in dry socket incidence and there was a 
higher incidence when three cartridges were used (38).
With respect to the menstrual cycles and oral contra-
ceptive use, Eshghpour et al. (39) found a decreased in-
cidence of dry socket in those patients who underwent 
the extraction during their menstrual periods and a 
higher incidence in those who consumed oral contra-
ceptives and underwent the extraction in the middle of 
their menstrual cycles, due to increased fibrinolytic ac-
tivity produced by the drug. These authors describe an 
increase in dry socket incidence since the introduction 
of oral contraceptives in the 1960s. Nonetheless, Par-
hasarathi et al. (46) did not find any differences when 
contraceptives were used. This difference may be at-
tributed to the lower amount of estrogen present in cur-
rent oral contraceptives (50). 
Abu Younis et al. (45) believes that single tooth extrac-
tions have a higher risk factor as compared to multiple 
extractions since the second procedure is performed 
when there is periodontal disease and is therefore a sim-
pler procedure. The results of four other articles included 
in the review (42-45) support the relationship between 
elevated surgical difficulty and dry socket, since trauma 
favors delayed healing through compression of the bony 
lining of the socket, thrombosis in underlying vessels, 
reduced tissue resistance, and predisposes the wound to 
infection (44). Parhasarathi et al. (46) also points out this 
out as the reason for the higher incidence of dry socket in 
posterior teeth, although it is less prevalent in mandibular 
teeth in contrast to what Oginni states in his article (44).
Professional experience was only analyzed in one ar-
ticle (46), showing a higher incidence in those surgeries 
carried out by specialists, but as the authors themselves 
point out the results seem to be biased due to the greater 
difficulty involved in these extractions. Parhasarathi 
et al. (46) were the only ones who found a higher in-
cidence of dry socket in patients taking antipsychotic 
and antidepressant drugs (OR 5.9), possibly due to the 
drug-induced hyposalivation that may reduce salivary 
protective components. 
Only Oginni (44) states the importance of insisting on 
good oral health in order to reduce incidence of dry 
socket.
Finally, with reference to age and gender as risk fac-
tors, all of the authors except Eshghpour and Nejat (38) 
described an increase of dry socket incidence with age, 
with an increased likelihood of 1.9 times per year, ac-
cording to Haraji and Rakhshan (42). This fact can be 
attributed to a slower metabolism, worse healing and a 
weaker immune system (42). Only Malkawi et al. (41) 
found a higher incidence in men although the rest of the 
articles did not find significant differences with regard 
to the patient’s gender.
Some limitations encountered during the review pro-
cess were the lack of consensus in the preventive meth-
ods used in the articles included in the review, being the 
formulation and dosage of the method studied differ-
ent in each article, and therefore their comparison was 
quite challenging. Also, the diversity of the risk factors 
considered in the articles included made it difficult to 
compare all the studies with accuracy. 
Conclusions
Chlorhexidine administration or platelet rich plasma re-
duce dry socket development. Antibiotic prescriptions 
do not have a preventive effect on postoperative inflam-
matory complications.
Age, history of previous infection and difficulty of ex-
traction are risk factors for developing dry socket and 
should therefore be taken into account by the clinician 
when carrying out the procedure. There is no consensus 
that tobacco use and menstrual cycles play a role in the 
development of dry socket.
After the article’s analysis and according to their scien-
tific quality, a level C recommendation is given to all 
the therapeutic procedures proposed for preventing dry 
socket.
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